Migraine headaches. Migraine
Conditions
Interventions
Intervention 1: Intervention Group 1 (Levetiracetam): These patients will receive levetiracetam which will start at a dose of 250 milligrams per day in the first week followed by an increased dose of
Sponsors
Birjand University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Presence of migraine headaches (headache attacks over 3 attacks per month; each attack with an interval of more than 48 hours of relief from other attacks) Age from 18 to 65 years Non-use of other anti-migraine drugs since at least one month ago No allergy to levetiracetam, sodium valproate, and nortriptyline or their compounds Absence of acute migraine resistant to treatment Not having severe mental disorders Absence of neurodegenerative disorders No malignancy Absence of pain disorders No severe infection Informed consent for participation
Exclusion criteria
Exclusion criteria: Pregnant or breast-feeding women Irregular consumption of medications Suffering from severe drug side-effects during the course of the study, which may change treatment regimen Treatment-resistant acute migraine Severe psychiatric disorders Drug or alcohol dependence Renal dysfunction Excessive use of acute migraine drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Headache severity. Timepoint: At the end of intervention. Method of measurement: Visual analogue scale.;Frequency of headache incidence. Timepoint: After intervention. Method of measurement: Patient daily notes during intervention.;Side effects (digestive, nervous, etc.). Timepoint: After intervention. Method of measurement: Patient daily notes during intervention. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Ahani
Birjand University of Medical Sciences
Outcome results
None listed